The Fund Named After the Horse

Every owner whose horse competes at a recognized or FEI-sanctioned show has signed a document most people read for exactly as long as it takes to find the signature line: the Horse Participation Consent Agreement, the paperwork that decides who is allowed to put a needle in a horse when its own trainer is not standing there. In April 2024, a 13-year-old Oldenburg gelding named Chromatic BF finished third in a 1.60m class at the FEI Jumping World Cup Final in Riyadh, was medicated that night by a USEF team veterinarian nobody on his own team had spoken to, and died in his stall roughly ninety minutes later. Two years on, the fund built in his name has just taken its second round of donor money. The facts of what happened are not in dispute. What is worth asking is whether the fund actually answers the question his death raised.

What the Necropsy Found

The necropsy identified the cause of death as severe pulmonary hemorrhage. Separately, USEF's own review, completed roughly four months after the incident, concluded that the medications administered to Chromatic that evening -- Legend, Adequan, Traumeel, Arnica, and Selevit among them -- were the most probable cause of death. Those medications were given by a USEF team veterinarian without prior consultation with Chromatic's own connections, under an agreement that, at the time, gave the federation's representatives broad latitude to treat a horse in its care.

The Fix Nobody Should Object To

USEF's response, to its credit, was not silence. In August 2024 the federation announced three changes: a revised consent agreement requiring the athlete's prior approval before a team veterinarian administers medication at an international competition, barring an emergency; a continuing-education program for USEF team veterinarians; and an education and research fund established in Chromatic's name. That fund, now formally The Chromatic Fund, runs as a partnership between the American Association of Equine Practitioners, USEF, Chromatic's breeder KC Branscomb, and The Foundation for the Horse, with grant applications reviewed by volunteer AAEP-member veterinarians rather than by USEF staff. Its first round, in 2025, committed nearly $100,000 to two legitimate, peer-reviewed research questions: a UC Davis study led by Dr. Carrie Finno examining whether high-dose vitamin E supplementation raises bleeding risk, and a North Carolina State study led by Dr. Lauren Schnabel comparing the safety of single high-dose versus repeated low-dose corticosteroid injections. USEF chief executive Bill Moroney described the intent plainly: "We didn't want to reinvent the wheel -- we wanted to rely on a process that already has credibility in the veterinary research community." That is a defensible instinct, and a better one than most sports manage after a fatality that reflects badly on their own staff.

What the Money Doesn't Buy

In 2026, Ariat, USEF, and Branscomb committed a combined $200,000 to the fund's second round -- a real increase, and one accompanied by genuine enthusiasm from its backers. Ariat's Susan Alcala called it an investment in "initiatives that help keep them healthy and safe." But look closely at what the fund is actually built to study, versus what Chromatic's death actually exposed. Both funded projects concern dosing and drug safety -- real, useful questions for sport horse medicine generally. Neither examines the specific failure the necropsy pointed to: that a single veterinarian, acting alone, had the standing authority to medicate a horse without consulting anyone who knew that horse, and that no one in that stable that night was positioned to say wait. The revised consent agreement closes that particular door procedurally. No part of the research fund has been directed at studying why the door was open as long as it was, or what happens to a team veterinarian whose judgment in a specific case turns out to have been wrong. A 2024 scoping review in the Equine Veterinary Journal, led by researchers at the University of Bristol, found that medication use in performance horses is already the most commonly cited ethical concern in the equine sports medicine literature, and that competing stakeholder interests and the design of governing bodies' own rules are recurring structural themes behind it. Chromatic's case is not an anomaly the literature failed to anticipate. It is close to the textbook example.

Two Federations, Two Different Answers

The more instructive contrast may not be internal to USEF at all. Effective January 1, 2025, the FEI's own Veterinary Regulations removed a standing exemption that had allowed injection or infusion up to 1000hrs on the day of competition for horses showing later that evening. The new rule is blunter than anything USEF has proposed: no treatment whatsoever, beyond a genuine emergency, on the day a horse competes -- full stop, regardless of ride time, regardless of who is asking. Nothing in the public record ties that change directly to Chromatic's case, and it would be unfair to claim otherwise. But the contrast in method stands on its own. One governing body closed a category of risk by rule. The other narrowed consent, funded a study of drug dosing, and asked owners to read a form more carefully than they used to.

For a hunter or jumper owner sending a horse to a recognized show under someone else's supervision, or shopping for one that will, the practical lesson sits closer to home than federation politics. That consent agreement is not boilerplate. It is the actual document governing who may treat a horse in a stall you are not standing in, and what recourse exists if that judgment is wrong. Read it as carefully as you would a vetting report before adding a horse to the string from Notting Hill Equine's current hunters and jumpers, because the day that form matters most is the day you are not in the room to be asked.